Concepedia

Melissa Martínez

MM

Statistics

Publications

12

Citations

1.3K

H-Index

11

Active since

2003

Affiliations

Indiana University – Purdue University Indianapolis(Current)

Indiana University School of Medicine

University of New Mexico

Vall d'Hebron Institute of Oncology

Janssen (United States)

Melissa Martínez is an author at Indiana University – Purdue University Indianapolis specializing in medicine, pharmacology, and oncology.

Publications per year

2003–2024

12

Publications

12

Trends and comparison of female first authorship in high impact medical journals: observational study (1994-2014)

Giovanni Filardo, Briget da Graca, Danielle Sass et al. · BMJ · 2016 · 466 citations · Full text

Public Health, Biostatistics, Internal Medicine +15

Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC

Byoung Chul Cho, Shun Lu, Enriqueta Felip et al. · New England Journal of Medicine · 2024 · 375 citations · Full text

Medicine, Oncology, Pharmacology +14

Clinical and Histologic Features of Azithromycin-Induced Liver Injury

Melissa Martínez, Raj Vuppalanchi, Robert J. Fontana et al. · Clinical Gastroenterology and Hepatology · 2014 · 133 citations · Full text

Medicine, Pathobiology, Pharmacotherapy +14

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer

Byoung Chul Cho, Enriqueta Felip, Hidetoshi Hayashi et al. · Future Oncology · 2021 · 93 citations · Full text

Medicine, Oncology, Pharmacology +14

LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial

B.C. Cho, Enriqueta Felip, Alexander I. Spira et al. · Annals of Oncology · 2023 · 83 citations · Full text

Medicine, Oncology, Pharmacology +13

1–5 of 12